Idarubicin

Drug Profile

Idarubicin

Alternative Names: DMDR; FCE 22723; Idamycin; Idarubicinol; IMI 30; NSC 256439; Zavedos; Zavedos Oral

Latest Information Update: 28 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Antineoplastics; Cytostatic antibiotics; Daunorubicins
  • Mechanism of Action DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Acute nonlymphocytic leukaemia; Breast cancer; Leukaemia

Most Recent Events

  • 21 Oct 2013 Biomarkers information updated
  • 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
  • 07 Sep 2000 Investigation in Chronic myeloid leukaemia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top